Head-to-head · WeighScore
Omada Health vs Sprout Health
The verdict
Sprout Health takes it — 86.4/100 to 55.6/100.
Sprout Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A LegitScript-certified desk that pairs low-cost compounded semaglutide and tirzepatide with a real brand-name Wegovy and Zepbound path — and a near-frictionless, often visit-free start.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Omada Health | Sprout Health |
|---|---|---|
| WeighScore | 55.6/100 | 86.4/100 |
| Grade | C | B |
| Scorecard rank | #435 | #6 |
| Semaglutide | Not disclosed | $149/mo |
| Tirzepatide | Not disclosed | $199/mo |
| Coverage | Coverage not published | Not disclosed |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Graded #6 · B
Strengths
- LegitScript-certified with a listed address and contact line
- Both compounded ($149 semaglutide / $199 tirzepatide) and a genuine brand-name Wegovy/Zepbound route
- Low-friction intake — no labs and often no telehealth visit required
Where it loses points
- Compounded semaglutide and tirzepatide are not FDA-approved
- No oral or sublingual route — injectable only
- Thin transparency — no named medical director, and state availability is quiz-gated
- "No labs, no visit" convenience also means lighter clinical oversight
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.